Vivos Therapeutics, Inc.
VVOS
$4.20
-$0.40-8.70%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -5.77% | -11.79% | 13.85% | 16.93% | 19.41% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -5.77% | -11.79% | 13.85% | 16.93% | 19.41% |
| Cost of Revenue | 21.88% | 1.69% | 38.14% | -1.80% | 8.17% |
| Gross Profit | -20.41% | -22.10% | 0.38% | 33.60% | 26.36% |
| SG&A Expenses | 50.14% | -5.85% | -21.64% | -7.71% | -31.31% |
| Depreciation & Amortization | 111.03% | 21.23% | -3.36% | -2.67% | -2.03% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 44.99% | -3.75% | -11.88% | -6.28% | -24.29% |
| Operating Income | -151.29% | -3.51% | 32.11% | 27.34% | 57.14% |
| Income Before Tax | -159.74% | -2.68% | 33.62% | -24.99% | 65.09% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -159.74% | -2.68% | 33.62% | -24.99% | 65.09% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -159.74% | -2.68% | 33.62% | -24.99% | 65.09% |
| EBIT | -151.29% | -3.51% | 32.11% | 27.34% | 57.14% |
| EBITDA | -154.55% | -2.80% | 33.18% | 28.42% | 59.01% |
| EPS Basic | 7.71% | 72.43% | 86.97% | 65.06% | 87.05% |
| Normalized Basic EPS | 7.71% | 72.42% | 86.97% | 65.06% | 87.05% |
| EPS Diluted | 7.71% | 72.43% | 86.97% | 65.06% | 87.05% |
| Normalized Diluted EPS | 7.71% | 72.42% | 86.97% | 65.06% | 87.05% |
| Average Basic Shares Outstanding | 181.48% | 272.38% | 409.47% | 257.65% | 169.64% |
| Average Diluted Shares Outstanding | 181.48% | 272.38% | 409.47% | 257.65% | 169.64% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |